Interview with Tong-Soo Chung, Head, Invest Korea
Could you please give a brief presentation of Invest Korea to our readers? Invest Korea is the national investment promotion agency, responsible for attracting FDI into Korea. We have existed…
Address: Room A-101, Namsong Bldg., 260-199 Itaewon-dong, Yongsan-gu Seoul, 140-200, Republic of Korea
Tel: +82 2 796 1056
Web: http://crm.cegedim.com/Pages/default.aspx
Cegedim was created in 1969 by Jean-Claude Labrune, a French visionary entrepreneur who focused on the pharmaceutical industry to provide companies with tailored services that help them build successful commercial strategies. In the late 70’s the first Customer Relationship Management solution designed for the Pharmaceutical industry was launched in France and quickly became a standard. With the success of its solutions, Cegedim quickly expanded its business internationally. In May 2007, Cegedim reinforced its global presence and leadership with the acquisition of Dendrite International, a US based company leading the SFA business in the healthcare sector on its continent as well as in Asia. This successful integration gave birth to a uniquely capable global entity providing Life Sciences ready CRM solutions. Today the new company renamed Cegedim Relationship Management does business in over 80 countries and accounts for more than 50 percent of the Cegedim Group’s annual revenues of $1.1 billion. Around the world, Cegedim Relationship Management works with companies behind the scenes to develop the most appropriate solutions that effectively manage the complex regulatory environment, minimize risks and decrease costs. Laurent Labrune, Group founder’s son, is the Chief Executive Officer of the new global organisation since 2007. He brought a wealth of creativity, innovation and expertise with a strong and knowledgeable management team. Altogether, they effectively made strategic choices for the long term leadership of the company.
Could you please give a brief presentation of Invest Korea to our readers? Invest Korea is the national investment promotion agency, responsible for attracting FDI into Korea. We have existed…
Boryung has a very interesting history, starting as a pharmacy in Seoul and going on to become one of the top 10 pharmaceutical companies in South Korea. What can you…
What drove you to make the move from the academia to the business sector when you decided to establish Medy-Tox in 2000? I founded Medy-tox in the year 2000, in…
What are the origins of Lundbeck in Korea and your involvement in its establishment? I joined Lundbeck just before it was officially established in Korea in April 2002. We started…
Though you have recently been appointed as President of KRIBB, your history with the institute goes quite far back. Could you please briefly explain the role it plays within South…
Could you please introduce Shinpoong, which you founded in 1962, and mention the main milestones of this unique company in the Korean pharmaceutical industry? I founded Shinpoong in a very…
Novartis’ Head Office in Basel, Switzerland as well as several prior international assignments in Asia and Europe. What do you find as the most interesting particularities of the pharmaceutical sector…
Please introduce the Korean Food and Drug Administration (KFDA) and its main health-related responsibilities within the Korean government… The KFDA’s main duty is to cooperate and support with domestic and…
How would you rate South Korea’s healthcare system when compared to regional peers and other OECD countries – main strong points and room for improvement? Since the introduction of the…
You have a very long track record working with Novo Nordisk in Asia. What is your perspective on the Diabetes explosion that has been taking place in this part of…
You have recently taken over the position as head of AstraZeneca in South Korea, after several years working in China. What view did you have of the Korean pharmaceutical sector…
You are one of the foreign multinational directors with most time in the Korean pharmaceutical industry, since 2003. What is your assessment of the direction the market has taken in…
See our Cookie Privacy Policy Here